Acute myeloid leukemia (AML) study
The Acute myeloid leukemia (AML) study is enrolling people who have been newly diagnosed with AML but who have not started chemotherapy and people with AML who have relapsed, but not yet started a new course of chemotherapy. This study will include 75 patients with AML.
Principal Investigators for Acute myeloid leukemia (AML) study
Anuj Agarwala, M.D.
Community Regional Cancer Care
Mark Browning, M.D.
Hematology Oncology Associates of SW Indiana
Wael Harb, M.D.
Horizon Oncology Research, Inc.
Stephen Rubenstein, M.D.
St. Francis Medical Group Oncology & Hematology Specialists